BALPHARMA

Bal Pharma financials

Market cap
₹171 Cr
Sector
Healthcare

What Bal Pharma Limited does

Bal Pharma Limited manufactures Active Pharmaceutical Ingredients (APIs) and pharma intermediates as well as finished dosage formulations (FDFs) such as tablets, capsules, syrups, IV infusions, ophthalmic and cream/ointment preparations, across therapeutic areas including anti-diabetes, anti-histamine, anti-inflammatory, cardiology and dermatology. It runs six manufacturing units across Karnataka, Maharashtra, Uttarakhand and Rajasthan, selling APIs and formulations domestically through its own field-force/distributor network and brands (Diabend, Glyduz, Servetus, Vibrant, Lifezen) and exporting under its own brand names or via registered third-party sellers and institutional/government tenders.

Segments

  • API / Intermediates
  • Finished Dosage Formulations (FDF)
  • Herbal (Bal Vedics)
  • Institutional Sales
  • OTC (Lifezen)
Manufacturing facilities
6 (3 API/Intermediates + 3 FDF, across Karnataka, Maharashtra, Uttarakhand & Rajasthan; one FDF unit non-operational, held for strategic purpose)
API/Intermediates installed capacity
370 tonnes per annum
FDF installed capacity
~3 billion tablets + 490 million capsules + 10 million creams/tubes per annum
API/Intermediates portfolio
22+ active molecules
Finished dosage formulations portfolio
200+ formulations across 20 therapeutic segments
Employee strength
1000+
Founded 1992Headquarters Bengaluru, Karnataka, IndiaEmployees 1,000 (FY23) Company website

Quarterly results

Q1 FY27: revenue up 34.7%, net profit up 262.5% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue75 73 82 66 74 −1%87 +20%84 +3%88 +35%
EBITDA7 8 8 6 6 −23%10 +22%11 +36%8 +29%
Net profit1 1 6 0 1 −35%2 +183%4 −34%1 +262%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +21.6% 1Y

₹60₹80₹100Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹88.37 on 10 Sept 2025 → ₹107.42. High ₹114.45 (9 Sept 2026), low ₹60.42 (30 Mar 2026).

Financials, as filed

Revenue fell 4.2% a year over 2 years, FY24 to FY26. Operating margin widened to 10.4%.

Year endingFY24FY25FY26
Revenue₹339 Cr₹303 Cr₹311 Cr
Operating profit₹32 Cr₹30 Cr₹32 Cr
Operating margin9.3%9.8%10.4%
Interest₹15 Cr₹17 Cr₹17 Cr
Depreciation₹9 Cr₹9 Cr₹11 Cr
Net profit₹9 Cr₹8 Cr₹7 Cr
Net margin2.8%2.6%2.2%
Cash from operations₹29 Cr₹20 Cr₹30 Cr
Free cash flow₹18 Cr₹2 Cr₹8 Cr
ROCE11.0%10.0%9.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹15 Cr₹15 Cr₹16 Cr₹16 Cr₹16 Cr₹16 Cr
Reserves₹64 Cr₹72 Cr₹80 Cr₹77 Cr₹62 Cr₹88 Cr
Borrowings₹104 Cr₹98 Cr₹125 Cr₹134 Cr₹155 Cr₹154 Cr
Other liabilities₹78 Cr₹104 Cr₹126 Cr₹108 Cr₹116 Cr₹133 Cr
Total liabilities₹262 Cr₹290 Cr₹348 Cr₹334 Cr₹349 Cr₹391 Cr
Fixed assets₹53 Cr₹53 Cr₹63 Cr₹79 Cr₹92 Cr₹94 Cr
Capital work in progress₹0 Cr₹1 Cr₹0 Cr₹0 Cr₹3 Cr₹7 Cr
Investments₹8 Cr₹8 Cr₹8 Cr₹9 Cr₹0 Cr₹4 Cr
Other assets₹200 Cr₹227 Cr₹276 Cr₹245 Cr₹253 Cr₹285 Cr
Total assets₹262 Cr₹290 Cr₹348 Cr₹334 Cr₹349 Cr₹391 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

The ownership split has held steady since Jun 2025. The shareholder count shrank 5% to 14,974.

Promoters
50.9%
FIIs
0.1%
Public
49.0%

Since Jun 2025

  • Promoters 0.00 pp
  • FIIs 0.00 pp
  • Public 0.00 pp

How it drifted, 12 quarters

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 51.6%, FIIs 0.1%, Public 48.3%.Dec '23: Promoters 51.2%, FIIs 0.1%, Public 48.6%.Mar '24: Promoters 51.2%, FIIs 0.1%, Public 48.6%.Jun '24: Promoters 51.2%, FIIs 0.1%, Public 48.6%.Sep '24: Promoters 50.9%, FIIs 0.1%, Public 49.0%.Dec '24: Promoters 50.9%, FIIs 0.1%, Public 49.0%.Mar '25: Promoters 50.9%, FIIs 0.1%, Public 49.0%.Jun '25: Promoters 50.9%, FIIs 0.1%, Public 49.0%.Sep '25: Promoters 50.9%, FIIs 0.2%, Public 48.9%.Dec '25: Promoters 50.9%, FIIs 0.1%, Public 49.0%.Mar '26: Promoters 50.9%, FIIs 0.1%, Public 49.0%.Jun '26: Promoters 50.9%, FIIs 0.1%, Public 49.0%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Bal Pharma Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Shailesh Siroya 17.24%unchanged
Micro Labs Limited 12.64%newly disclosed
Anita Siroya 6.59%unchanged
Prakash Chandra Jain 3.44%−0.21 pp
Ram Keshav Murthy 3.31%unchanged
Anand Surana 3.30%unchanged
Chandraprakash Dheerajmal Siroya 3.06%unchanged
Dilip Surana 2.98%unchanged
Naresh D P 1.88%unchanged
Shreya Mardia 1.88%unchanged
Asha Tapidas Dodhia 1.84%unchanged
Archana Surana 1.79%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Bal Pharma Limited

Guides on how to read this kind of business and the numbers that matter.